Eczema Treatment: Steroids, Biologics, Natural Options

The Treatment Ladder

Eczema (atopic dermatitis) treatment follows a stepwise approach based on severity. The critical point most patients miss: the foundation (moisturizing, trigger avoidance, and skin care routine) must be in place at every severity level. Adding medications on top of a broken skin care foundation produces poor results [1].

Step 1: Skin Care Foundation (All Patients)

Moisturizers (Emollients)

The single most important intervention for eczema. Eczema skin has a defective skin barrier (often involving filaggrin gene mutations) that allows transepidermal water loss and allergen/irritant penetration. Daily moisturizing restores barrier function [2].

Choosing the right moisturizer:

• Ointments (petroleum jelly, Aquaphor): Most occlusive, best barrier repair. Greasy feel limits daytime use for some patients. Best applied at night.
• Creams (CeraVe, Vanicream, Cetaphil): Good balance of efficacy and cosmetic acceptability. Look for ceramides, which directly restore the lipid bilayer.
• Lotions: Least occlusive, evaporate quickly. Insufficient for active eczema. Fine for very mild or inactive disease.

Application protocol: apply within 3 minutes of bathing (on damp skin) to lock in moisture. Full body, at least once daily. Twice daily on active areas. Use liberally: a child needs 250 g/week, an adult needs 500 g/week for full coverage.

Bathing Practices

• Lukewarm water (not hot), 5-10 minutes
• Fragrance-free, soap-free cleanser only on dirty areas (groin, axillae, feet). Avoid cleansing eczema-prone areas unless actually soiled.
• Pat dry gently, do not rub
• Apply moisturizer immediately
• Bleach baths (quarter cup regular bleach in a full bathtub, 2x/week) reduce Staphylococcus aureus colonization, which triggers flares in 90% of eczema patients [3]

Trigger Avoidance

• Fragrance-free everything: detergent, soap, lotion, dryer sheets
• Cotton or bamboo clothing (avoid wool and synthetic fabrics against skin)
• Temperature regulation: overheating and sweating trigger flares
• Dust mite reduction if sensitized: encased pillows and mattress, hot-water washing of bedding

Step 2: Topical Anti-Inflammatory Treatment

Topical Corticosteroids (TCS)

The first-line anti-inflammatory for eczema flares. Available in 7 potency classes (Class I strongest, Class VII weakest in the US system). Choosing the right potency for the right location is the key skill [4]:

Addressing steroid phobia: topical corticosteroid side effects (skin thinning, stretch marks, telangiectasia) occur with prolonged continuous use of inappropriate potency on thin-skinned areas. Used correctly (right potency, right location, 2-4 week courses with maintenance), TCS are safe. Undertreatment from steroid fear causes more disease burden than appropriate steroid use [5].

Proactive Maintenance (“Weekend Therapy”)

Instead of waiting for flares and treating reactively, apply mid-potency TCS to previously affected areas 2x/week even when the skin appears clear. This approach reduces relapse rates by 50-70% in clinical trials and is now the standard recommendation for patients with frequently relapsing eczema.

Topical Calcineurin Inhibitors (TCI)

• Tacrolimus 0.03% and 0.1% (Protopic): As effective as medium-potency TCS without atrophy risk. Ideal for face, eyelids, and genital areas for long-term use. Common side effect: burning/stinging on application (resolves after a few days).
• Pimecrolimus 1% (Elidel): Less potent than tacrolimus. Best for mild-to-moderate disease on sensitive areas. Good for maintenance therapy.

Topical PDE4 Inhibitor

• Crisaborole 2% (Eucrisa): A non-steroidal, non-calcineurin inhibitor option for mild-to-moderate eczema. Less effective than medium-potency TCS but offers a steroid-free option. Main side effect: application site stinging.

Topical JAK Inhibitor

• Ruxolitinib 1.5% cream (Opzelura): Approved for mild-to-moderate atopic dermatitis. Anti-itch effect is rapid (within 36 hours). Provides a new mechanism for patients who prefer non-steroidal options. Use limited to 20% BSA and 60 g per cycle due to systemic absorption concerns.

Step 3: Phototherapy

Narrowband UVB (NB-UVB) is effective for moderate-to-severe eczema that is widespread and poorly controlled with topicals alone. Treatment is 2-3 times weekly for 8-12 weeks in a light booth or with a home unit [6].

Mechanism: UVB suppresses T-cell mediated skin inflammation, reduces pruritus, and improves barrier function. It is safe for long-term use and can be combined with topical therapies.

Limitations: requires frequent clinic visits (or a home unit), time-consuming, and not practical for localized disease. Most effective for trunk and limb eczema.

Step 4: Systemic Therapies

Dupilumab (Dupixent)

A monoclonal antibody blocking IL-4 and IL-13, the key type 2 inflammatory cytokines driving eczema. Approved for moderate-to-severe atopic dermatitis in adults and children aged 6 months and older [7].

• EASI-75 (75% improvement) in 44-51% of patients at 16 weeks (vs. 12-15% placebo)
• Dramatic itch reduction (average 50-60% reduction in peak pruritus score)
• Onset of itch relief within 2 weeks; skin improvement over 4-16 weeks
• Self-administered subcutaneous injection every 2 weeks
• Main side effect: conjunctivitis (10-20%), injection site reactions
• No immunosuppressive monitoring required. No increased infection risk.

Dupilumab was a paradigm shift for eczema treatment. For the first time, patients with severe, refractory eczema had an effective, safe, long-term option.

JAK Inhibitors (Oral)

• Abrocitinib (Cibinqo): JAK1 inhibitor. 100-200 mg daily oral. Rapid onset (itch improvement within days). EASI-75 in 44-63%. Risk considerations: herpes zoster, acne, nausea, headache.
• Upadacitinib (Rinvoq): JAK1 inhibitor. 15-30 mg daily oral. EASI-75 in 62-73% (highest clearance rates among current systemic options). Outperformed dupilumab in head-to-head trials for skin clearance, though safety profile is narrower.
• Baricitinib (Olumiant): JAK1/JAK2 inhibitor. 2-4 mg daily. Approved in Europe and some other markets for eczema. Lower efficacy than abrocitinib and upadacitinib.

JAK inhibitors require monitoring: CBC, liver function, lipids, and screening for tuberculosis and hepatitis before starting. Risk of herpes zoster is elevated; vaccination before starting is recommended.

Tralokinumab (Adbry)

An IL-13-specific monoclonal antibody. Subcutaneous injection every 2 weeks. EASI-75 in 25-33% as monotherapy. Less effective than dupilumab in indirect comparisons but may benefit patients who do not respond to or cannot tolerate dupilumab.

Traditional Immunosuppressants

Used less frequently now that biologics and JAK inhibitors are available, but still relevant when access or cost is a barrier:

• Cyclosporine: Rapid onset, effective. Limited to 1-2 years due to nephrotoxicity. Useful as a bridge to biologic therapy.
• Methotrexate: Slow onset (8-12 weeks). Modest efficacy. Lower cost. Weekly dosing.
• Azathioprine: Slow onset. Used when other options fail or are unavailable. TPMT testing required before starting.
• Mycophenolate mofetil: Off-label. Moderately effective. Used as a steroid-sparing agent.

Managing Itch

Pruritus is the most disabling symptom of eczema and the primary driver of the itch-scratch cycle that worsens disease. Beyond anti-inflammatory treatment:

• Keep nails short: Reduces scratch damage
• Cold compresses: Immediate but temporary itch relief through TRPM8 activation
• Oral antihistamines: Sedating antihistamines (hydroxyzine, diphenhydramine) help with nighttime itch through sedation, not direct anti-itch action. Non-sedating antihistamines (cetirizine, loratadine) are not effective for eczema itch.
• Menthol-containing creams (0.5-1%): Topical counter-irritant that provides temporary itch relief

Wet Wrap Therapy

A highly effective technique for breaking severe flare cycles. Protocol [8]:

1. Bathe in lukewarm water for 10 minutes
2. Apply topical corticosteroid (diluted or standard potency, per provider guidance) to affected areas
3. Apply a thick layer of emollient over the entire body
4. Cover with a damp layer of tubular bandage or wet cotton clothing
5. Cover with a dry layer on top
6. Leave on for 2-4 hours (or overnight)

Wet wraps increase topical medication absorption by 10x, provide physical barrier against scratching, cool the skin, and restore hydration. Typically used for 3-7 consecutive days during severe flares.

Natural and Complementary Approaches

• Sunflower seed oil: Contains linoleic acid, which supports skin barrier repair. Applied topically, it has shown benefit in neonatal studies. Use as a supplement to (not replacement for) standard emollients.
• Coconut oil: Has antimicrobial properties against S. aureus. A small RCT showed improvement in SCORAD scores versus mineral oil. Safe as a supplemental emollient.
• Evening primrose oil: Contains gamma-linolenic acid (GLA). Oral supplementation studies show mixed results. A 2013 Cochrane review found insufficient evidence to recommend.
• Probiotics: Evidence for prevention (prenatal/early life supplementation reduces eczema risk by 20-30%). Evidence for treatment of established eczema is weaker, with some benefit for Lactobacillus rhamnosus strains [9].
• Vitamin D: Deficiency is common in eczema. Supplementation may reduce winter flare severity, particularly in children.

When to See a Dermatologist

• Eczema covers more than 10% of body surface area
• Symptoms are not controlled with OTC moisturizers and low-potency steroids
• Sleep is disrupted by itch more than 2 nights per week
• Recurrent skin infections (crusting, weeping, honey-colored drainage) suggest S. aureus infection requiring antibiotics
• Eczema affects the face, hands, or genitals and topicals are not sufficient
• You want to discuss biologic or systemic therapy options

Related Reading

• Eczema: The Evidence-Based Guide (Pillar)
• Dyshidrotic Eczema: Hand and Foot Blistering Eczema Guide

References

1. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi:10.1111/jdv.14891
2. van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. doi:10.1002/14651858.CD012119.pub2
3. Huang JT, Abrams M, Tlougan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009;123(5):e808-e814. doi:10.1542/peds.2008-2217
4. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023
5. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-936. doi:10.1046/j.1365-2133.2000.03473.x
6. Garritsen FM, Brouwer MW, Limpens J, et al. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170(3):501-513. doi:10.1111/bjd.12645
7. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020
8. Nicol NH, Boguniewicz M. Wet wrap therapy in moderate to severe atopic dermatitis. Immunol Allergy Clin North Am. 2017;37(1):123-139. doi:10.1016/j.iac.2016.08.003
9. Zuccotti G, Meneghin F, Aceti A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy. 2015;70(11):1356-1371. doi:10.1111/all.12700